Immunotherapy in Thyroid Cancer: Current Strategies and Challenges

Area of Science:

• Endocrinology
• Oncology
• Immunology

Background:

• Thyroid cancer is the most common endocrine malignancy with rising global incidence.
• Conventional treatments struggle with advanced and aggressive thyroid cancers like anaplastic and refractory differentiated types.

Purpose of the Study:

• To explore immunotherapy as a novel therapeutic strategy for challenging thyroid cancer cases.
• To investigate the role of immune checkpoint inhibitors (ICIs) and immune cells in thyroid cancer.

Main Methods:

• Review of current literature on thyroid cancer treatment and immunotherapy.
• Analysis of the role of immune checkpoint inhibitors (PD-1/PD-L1, B7-H3) in enhancing antitumor immunity.
• Examination of immune cell involvement (CD4+, CD8+, M2 macrophages) in the tumor microenvironment and their prognostic significance.

Main Results:

• Immune checkpoint inhibitors demonstrate potential in boosting antitumor responses against thyroid cancer.
• Specific immune cells (CD4+, CD8+, M2 macrophages) are identified as crucial players and potential biomarkers within the tumor microenvironment.
• Combination therapies involving ICIs with targeted or adoptive cell therapies are under investigation to enhance efficacy.

Conclusions:

• Immunotherapy, especially ICIs, offers a promising avenue for managing advanced and refractory thyroid cancers.
• Understanding the tumor microenvironment and immune cell dynamics is critical for optimizing treatment strategies.
• Overcoming challenges like tumor heterogeneity and immune evasion is key for future therapeutic advancements.